Prevention of cancer through immunization: Prospects and challenges for the 21st century

European Journal of Immunology

Volumn 37, Issue SUPPL. 1, 2007, Pages

  Frazer, Ian H ^a   Lowy, Doug R ^b   Schiller, John T ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Immunotherapy; Infection; Vaccines

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BCG VACCINE; CAGA PROTEIN; CAPSID PROTEIN; ENVELOPE PROTEIN; EPSTEIN BARR VIRUS VACCINE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP350; HELICOBACTER PYLORI VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 2; LATENT MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; PLACEBO; PROTEIN E6; PROTEIN E7; PROTEIN L1; PROTON PUMP INHIBITOR; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; UREASE; WART VIRUS VACCINE;

ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONDYLOMA; EPSTEIN BARR VIRUS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HERPES VIRUS INFECTION; HUMAN; IMMUNIZATION; IMMUNOPROPHYLAXIS; INFECTION CONTROL; INFECTION PREVENTION; KIDNEY CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOMA; NONHUMAN; ONCOGENE; PERSISTENT INFECTION; PRIORITY JOURNAL; STOMACH CANCER; SYNCOPE; UTERINE CERVIX CANCER; WART VIRUS;

ANIMALS; BACTERIAL VACCINES; CANCER VACCINES; HUMANS; NEOPLASMS; VIRAL VACCINES;

EID: 36248998908     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737820     Document Type: Article

References (52)

1. Parkin, D. M., The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006. 118: 3030-3044.
2. Campo, M. S., Bovine papillomavirus and cancer. Vet. J. 1997. 154: 175-188.
3. Peter, S. and Beglinger, C., Helicobacter pylori and gastric cancer: The causal relationship. Digestion 2007. 75: 25-35.
4. Bui, J. D. and Schreiber, R. D., Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 2007. 19: 203-208.
5. Parkin, D. M. and Bray, F., Chapter 2: The burden of HPV-related cancers. Vaccine 2006. 24 Suppl 3: S11-S25.
6. Zur Hansen, H., Human papillomaviruses and their possible role in squamous cell carcinomas. Curr. Top. Microbiol. Immunol. 1977. 78: 1-30.
7. Zur Hansen, H., de Villiers, E. M. and Gissmann, L., Papillomavirus infections and human genital cancer. Gynecol. Oncol. 1981. 12: S124-S128.
8. Lowy, D. R. and Howley, P. M., Papillomavirus. In Knipe, D. M. and Howley, P. M. (Eds.) Field's Virology. Lippincott Williams and Wilkins, Philadelphia 2007, pp 2299-2354.
9. Baseman, J. G. and Koutsky, L. A., The epidemiology of human papillomavirus infections. J. Clin. Virol. 2005. 32 Suppl 1: S16-S24.
10. Munoz, N., Bosch, F. X., Castellsague, X., Diaz, M., de Sanjose, S., Hammouda, D., Shah, K. V. and Meijer, C. J., Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 2004. 111: 278-285.
11. D'Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H. and Gillison, M. L., Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 2007. 356: 1944-1956.
12. Plummer, M., Schiff-man, M. A., Castle, P. E., Maucort-Boulch, D., Wheeler, C. M. and ALTS study group, A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 2007. 195: 1582-1589.
13. Stanley, M., Lowy, D. R. and Frazer, I. H., Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006. 24 Suppl 3: S106-S113.
14. Zhou, J., Sun, X. Y., Stenzel, D. J. and Frazer, I. H., Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991. 185: 251-257.
15. Rose, R. C., Bonnez, W., Reichman, R. C. and Garcea, R. L., Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles. J. Virol. 1993. 67: 1936-1944.
16. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R. and Schiller, J. T., Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 1992. 89: 12180-12184.
17. Ghim, S.-J., Jenson, A. B. and Schlegel, R., HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 1992. 190: 548-552.
18. Wheeler, C. M., Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat. Clin. Pract. Oncol. 2007. 4: 224-235.
19. Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A. C., Solomon, D., Bratti, M. C., Schiller, J. T. et al., Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007. 298: 743-753.
20. Schiller, J. T. and Nardelli-Haefliger, D., Chapter 17: Second generation HPV vaccines to prevent cervical cancer. Vaccine 2006. 24 Suppl 3: S147-S153.
21. Frazer, I. H., Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 2004. 4: 46-55.
22. Shepard, C. W., Simard, E. P., Finelli, L., Fiore, A. E. and Bell, B. P., Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 2006. 28: 112-125.
23. Lupberger, J. and Hildt, E., Hepatitis B virus-induced oncogenesis. World J. Gastroenterol. 2007. 13: 74-81.
24. Cutts, F. T. and Hall, A. J., Vaccines for neonatal viral infections: hepatitis B vaccine. Expert. Rev. Vaccines 2004. 3: 349-352.
25. Kundi, M., New hepatitis B vaccine formulated with an improved adjuvant system. Expert. Rev. Vaccines 2007. 6: 133-140.
26. Chang, M. H., Chen, C. J., Lai, M. S., Hsu, H. M., Wu, T. C., Kong, M. S., Liang, D. C. et al., Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 1997 336: 1855-1859.
27. Chang, M. H., Chen, T. H., Hsu, H. M., Wu, T. C., Kong, M. S., Liang, D. C., Ni, Y. H. et al., Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin. Cancer Res. 2005. 11: 7953-7957
28. Pol, S. and Michel, M. L., Therapeutic vaccination in chronic hepatitis B virus carriers. Expert. Rev. Vaccines 2006. 5: 707-716.
29. Davis, G. L., Krawczynski, K. and Szabo, G., Hepatitis C virus infection- pathobiology and implications for new therapeutic options. Dig. Dis. Sci. 2007. 52: 857-875.
30. Raza, S. A., Clifford, G. M. and Franceschi, S., Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br. J. Cancer 2007. 96: 1127-1134.
31. Levrero, M., Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006. 25: 3834-3847.
32. Lan, K. H., Lan, K. L., Lee, W. P., Sheu, M. L., Chen, M. Y., Lee, Y. L., Yen, S. H. et al., HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J. Hepatol. 2007. 46: 759-767.
33. Martinez-Donato, G., Capdesuner, Y., Costa-Rivero, N., Rodriguez, A., Morales-Grillo, J., Martinez, E., Gonzalez, M. et al., Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice. Mol. Biotechnol. 2007. 35: 225-236.
34. Leroux-Roels, G., Batens, A. H., Desombere, L, Van Den, S. B., Vander, S. C., Maertens, G. and Hulstaert, F., Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum. Vaccin. 2005. 1: 61-65.
35. Elmowalid, G. A., Qiao, M., Jeong, S. H., Borg, B. B., Baumert, T. F., Sapp, R. K., Hu, Z. et al., Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl. Acad. Sci. USA 2007. 104: 8427-8432.
36. Klein, E., Kis, L. L. and Klein, G., Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 2007. 26: 1297-1305.
37. Hislop, A. D., Taylor, G. S., Sauce, D. and Rickinson, A. B., Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 2007. 25: 587-617.
38. Moutschen, M., Leonard, P., Sokal, E. M., Smets, F., Haumont, M., Mazzu, P., Bollen, A. et al., Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007. 25: 4697-4705.
39. Turk, S. M., Jiang, R., Chesnokova, L. S. and Hutt-Fletcher, L. M., Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J. Virol. 2006. 80: 9628-9633.
40. Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S. et al., Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002. 347: 1652-1661.
41. Khanna, R., Moss, D. and Gandhi, M., Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat. Clin. Pract. Oncol. 2005. 2: 138-149.
42. Moss, D. J., Khanna, R. and Gandhi, M., The use of T-cell directed cellular therapies in Australia. Cytotherapy 2007. 9: 222-224.
43. Masmoudi, A., Toumi, N., Khanfir, A., Kallel-Slimi, L., Daoud, J., Karray, H. and Frikha, M., Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. Cancer Treat. Rev. 2007
44. Malaty, H. M., Epidemiology of Helicobacter pylori infection. Best. Pract. Res. Clin. Gastroenterol. 2007. 21: 205-214.
45. Robinson, K., Argent, R. H. and Atherton, J. C., The inflammatory and immune response to Helicobacter pylori infection. Best. Pract. Res. Clin. Gastroenterol. 2007. 21: 237-259.
46. Wilson, K. T. and Crabtree, J. E., Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007. 133: 288-308.
47. Peek, R. M. Jr. and Crabtree, J. E., Helicobacter infection and gastric neoplasia. J. Pathol. 2006. 208: 233-248.
48. McGee, D. J. and Mobley, H. L., Pathogenesis of Helicobacter pylori infection. Curr. Opin. Gastroenterol. 2000, 16: 24-31.
49. Clyne, M., Dolan, B. and Reeves, E. P., Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori. FEMS Microbiol. Lett. 2007. 268: 135-143.
50. Morihara, F., Fujii, R., Hifumi, E., Nishizono, A. and Uda, T., Effects of vaccination by a recombinant antigen ureB138 (a segment of the beta-subunit of urease) against Helicobacter pylori infection. J. Med. Microbiol. 2007. 56: 847-853.
51. Svennerholm, A. M. and Lundgren, A., Progress in vaccine development against Helicobacter pylori. FEMS Immunol. Med. Microbiol. 2007. 50: 146-156.
52. Graham, D. Y., Opekun, A. R., Osato, M. S., El-Zimaity, H. M., Lee, C. K., Yamaoka, Y., Qureshi, W. A. et al., Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004. 53: 1235-1243.